nifedipine has been researched along with Altitude Sickness in 51 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Altitude Sickness: Multiple symptoms associated with reduced oxygen at high ALTITUDE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-concentration NO inhalation on the basis of conventional and nifedipine therapies was very effective in the treatment of high-altitude pulmonary edema, which deserves further and larger scale investigation." | 9.08 | [Low-concentration nitrous oxide inhalation in the treatment of high-altitude pulmonary edema]. ( Ma, Y; Wang, W; Zhang, X, 1998) |
| "Twenty-one mountaineers (1 woman and 20 men) with a history of radiographically documented high-altitude pulmonary edema were randomly assigned to receive either 20 mg of a slow-release preparation of nifedipine (n = 10) or placebo (n = 11) every 8 hours while ascending rapidly (within 22 hours) from a low altitude to 4559 m and during the following three days at this altitude." | 9.07 | Prevention of high-altitude pulmonary edema by nifedipine. ( Bärtsch, P; Maggiorini, M; Noti, C; Oelz, O; Ritter, M; Vock, P, 1991) |
| "We have studied the prophylactic administration of nifedipine and its molecular mechanism involved in reducing the transvascular leakage and inflammation in rats under hypoxia." | 7.78 | Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB. ( M, C; Mathew, T; P, H; S K S, S; S, S, 2012) |
| "Low-concentration NO inhalation on the basis of conventional and nifedipine therapies was very effective in the treatment of high-altitude pulmonary edema, which deserves further and larger scale investigation." | 5.08 | [Low-concentration nitrous oxide inhalation in the treatment of high-altitude pulmonary edema]. ( Ma, Y; Wang, W; Zhang, X, 1998) |
| "Nifedipine has been shown effective for prevention and treatment of high altitude pulmonary edema (HAPE)." | 5.07 | Nifedipine does not prevent acute mountain sickness. ( Bärtsch, P; Goerre, S; Hohenhaus, E; Niroomand, F; Oelz, O; Vock, P, 1994) |
| "Twenty-one mountaineers (1 woman and 20 men) with a history of radiographically documented high-altitude pulmonary edema were randomly assigned to receive either 20 mg of a slow-release preparation of nifedipine (n = 10) or placebo (n = 11) every 8 hours while ascending rapidly (within 22 hours) from a low altitude to 4559 m and during the following three days at this altitude." | 5.07 | Prevention of high-altitude pulmonary edema by nifedipine. ( Bärtsch, P; Maggiorini, M; Noti, C; Oelz, O; Ritter, M; Vock, P, 1991) |
| "We have studied the prophylactic administration of nifedipine and its molecular mechanism involved in reducing the transvascular leakage and inflammation in rats under hypoxia." | 3.78 | Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB. ( M, C; Mathew, T; P, H; S K S, S; S, S, 2012) |
| "Both of aminophylline and nifedipine can attenuate pulmonary hypertension in patients with HAPE, but the effect of aminophylline was better than the effect of nifedipine." | 3.72 | [Hemodynamic effects of aminophylline and nifedipine in patients with high altitude pulmonary edema]. ( Cheng, GL; Gao, YQ; Li, SZ; Liou, FY; Mou, XB; Tang, HY; Ye, GL; Zhou, XB, 2004) |
| "High altitude pulmonary edema (HAPE) is characterized by marked pulmonary hypertension." | 2.67 | Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. ( Bärtsch, P; Maggiorini, M; Noti, C; Oelz, O; Ritter, M; Vock, P; Waber, U, 1992) |
| "High-altitude pulmonary edema is a non-cardiac edema that often precedes acute mountain sickness." | 2.42 | [Visiting high altitudes--healthy persons and patients with risk diseases]. ( Fischer, R, 2004) |
| "Acetazolamide 750 mg was also efficacious (2." | 2.41 | Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. ( Dumont, L; Mardirosoff, C; Tramèr, MR, 2000) |
| "Essentially, acute mountain sickness is self-limiting and benign." | 2.41 | [Mountaineering and altitude sickness]. ( Maggiorini, M, 2001) |
| "High-altitude pulmonary edema (HAPE) occurs in unacclimatized individuals who are rapidly exposed to altitudes in excess of 2450 m." | 2.39 | High-altitude pulmonary edema: current concepts. ( Hultgren, HN, 1996) |
| "Acetazolamide has been used in a dosage of 250 to 500 mg 12 to 24 h." | 2.38 | [Prevention and therapy of altitude sickness]. ( Maggiorini, M, 1993) |
| "Individuals susceptible to high altitude pulmonary edema also show increased hypoxia vasoconstriction of pulmonary arterioles." | 2.38 | [Who gets altitude sickness?]. ( Bärtsch, P, 1992) |
| "High altitude pulmonary edema (HAPE) is a life-threatening altitude illness that usually occurs in insufficiently acclimatized climbers in the first few days at altitudes above 2500 m." | 1.51 | Delayed-Onset High Altitude Pulmonary Edema: A Case Report. ( Acharya, S; Bhattarai, A; Wilkes, M; Yadav, JK, 2019) |
| "Oral nifedipine or placebo was administered to alternating patients." | 1.38 | Nifedipine for the treatment of high altitude pulmonary edema. ( Basnet, S; Deshwal, R; Iqbal, M, 2012) |
| "High altitude pulmonary edema (HAPE) is the leading cause of death from altitude illness and rapid descent is often considered a life-saving foundation of therapy." | 1.34 | Treatment of high altitude pulmonary edema at 4240 m in Nepal. ( Fagenholz, PJ; Gutman, JA; Harris, NS; Murray, AF, 2007) |
| "High-altitude pulmonary edema (HAPE) is a non-cardiogenic edema that is often preceded by symptoms of AMS." | 1.32 | [Acute mountain sickness and high-altitude pulmonary edema. How to protect the mountain climber from the effects of the "altitude haze"]. ( Bärtsch, P; Dehnert, Ch; Mairbäurl, H; Schneider, M, 2003) |
| "High altitude pulmonary edema is characterized hemodynamically by a markedly restricted pulmonary vascular bed." | 1.28 | The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: a comparison. ( Greene, ER; Hackett, PH; Hartig, GS; Levine, BD; Roach, RC, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.92) | 18.7374 |
| 1990's | 20 (39.22) | 18.2507 |
| 2000's | 13 (25.49) | 29.6817 |
| 2010's | 15 (29.41) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Luks, AM | 3 |
| Swenson, ER | 2 |
| Parise, I | 1 |
| Li, Y | 1 |
| Zhang, Y | 2 |
| Bhattarai, A | 1 |
| Acharya, S | 1 |
| Yadav, JK | 1 |
| Wilkes, M | 1 |
| Fischer, R | 2 |
| Maimaitiyimin, D | 1 |
| Tao, Y | 1 |
| Shi, W | 1 |
| Upur, H | 1 |
| Aikemu, A | 1 |
| Caravita, S | 1 |
| Faini, A | 1 |
| Bilo, G | 1 |
| Lang, M | 1 |
| Parati, G | 1 |
| Yanamandra, U | 1 |
| Nair, V | 1 |
| Singh, S | 1 |
| Gupta, A | 1 |
| Mulajkar, D | 1 |
| Yanamandra, S | 1 |
| Norgais, K | 1 |
| Mukherjee, R | 1 |
| Singh, V | 1 |
| Bhattachar, SA | 1 |
| Patyal, S | 1 |
| Grewal, R | 1 |
| Chopra, B | 1 |
| Chandramoorthi, GD | 1 |
| Piramanayagam, S | 1 |
| Marimuthu, P | 1 |
| Berendsen, RR | 1 |
| Willems, JH | 1 |
| Bosch, FH | 2 |
| Hulsebosch, R | 1 |
| Kayser, B | 2 |
| Ghosh, M | 1 |
| Biswas, D | 1 |
| Mukherjee, A | 1 |
| McIntosh, SE | 2 |
| Grissom, CK | 1 |
| Auerbach, PS | 1 |
| Rodway, GW | 2 |
| Schoene, RB | 3 |
| Zafren, K | 1 |
| Hackett, PH | 3 |
| Bailey, DM | 1 |
| Dehnert, C | 1 |
| Menold, E | 1 |
| Castell, C | 1 |
| Schendler, G | 1 |
| Faoro, V | 1 |
| Gutowski, M | 1 |
| Evans, KA | 1 |
| Taudorf, S | 1 |
| James, PE | 1 |
| McEneny, J | 1 |
| Young, IS | 1 |
| Mairbäurl, H | 2 |
| Bärtsch, P | 12 |
| Berger, MM | 1 |
| Mou, XB | 1 |
| Li, SZ | 1 |
| Gao, YQ | 1 |
| Liou, FY | 1 |
| Ye, GL | 1 |
| Tang, HY | 1 |
| Zhou, XB | 1 |
| Cheng, GL | 1 |
| Deshwal, R | 1 |
| Iqbal, M | 1 |
| Basnet, S | 1 |
| S K S, S | 1 |
| P, H | 1 |
| Mathew, T | 1 |
| S, S | 1 |
| M, C | 1 |
| Wagner, DR | 1 |
| Cushing, TA | 1 |
| Keyes, LE | 1 |
| Basnyat, B | 1 |
| Freer, L | 1 |
| Jones, BE | 1 |
| Stokes, S | 1 |
| McKenzie, S | 1 |
| Nilles, E | 1 |
| Stoddard, GJ | 1 |
| Dehnert, Ch | 1 |
| Schneider, M | 1 |
| Maggiorini, M | 7 |
| Fagenholz, PJ | 1 |
| Gutman, JA | 1 |
| Murray, AF | 1 |
| Harris, NS | 1 |
| Knobloch, J | 1 |
| Goerre, S | 2 |
| Wenk, M | 1 |
| Lüscher, TF | 1 |
| Niroomand, F | 2 |
| Hohenhaus, E | 2 |
| Oelz, O | 11 |
| Reinhart, WH | 2 |
| Vock, P | 5 |
| Hultgren, HN | 1 |
| Aslam, M | 1 |
| Khan, MZ | 1 |
| Dumont, L | 1 |
| Mardirosoff, C | 1 |
| Tramèr, MR | 1 |
| Wang, W | 1 |
| Zhang, X | 1 |
| Ma, Y | 1 |
| Roach, RC | 2 |
| Jamieson, A | 1 |
| Kerr, GW | 1 |
| Ritter, M | 5 |
| Noti, C | 4 |
| Waber, U | 4 |
| Hartig, GS | 1 |
| Greene, ER | 1 |
| Levine, BD | 1 |
| Jenni, R | 2 |
| Singh, A | 1 |
| Reeves, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness: A Randomized Controlled Trial[NCT02972411] | 30 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | |||
| Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness.[NCT01536288] | Phase 2 | 125 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Multicentric Evaluation of the Impact on Hypoxia Sensitivity of Patients With COVID-19[NCT05167357] | 90 participants (Anticipated) | Interventional | 2021-03-18 | Recruiting | |||
| Sickness Evaluation at Altitude With Acetazolamide at Relative Doses[NCT03828474] | Phase 1 | 108 participants (Actual) | Interventional | 2019-08-09 | Completed | ||
| Treatment of High-altitude Sleep Disturbance: A Double-blind Comparison of Temazepam Versus Acetazolamide.[NCT01519544] | 34 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen[NCT01522326] | 300 participants (Anticipated) | Interventional | 2012-03-01 | Completed | |||
| The Effect of Riociguat on Gas Exchange, Exercise Performance, and Pulmonary Artery Pressure During Acute Altitude Exposure[NCT02024386] | Phase 4 | 28 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Arterial blood samples will be obtained before, during, and after the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Samples will be obtained during the fifth minute of rest prior to exercise, during the third minute of each exercise level (referred to as stage below) and during the fifth minute post exercise. Cardiac output (CO) will be calculated using the Fick Principle: CO = V̇O2/(CaO2 - Cv̄O2) where CaO2 and Cv̄O2 represent the arterial and mixed venous oxygen content, respectively. CaO2 and CvO2 will be determined from analysis of the arterial blood samples using an IL GEM 4000 analyzer. VO2 will be reported as the final 30 secon average value of each stage. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | L/min (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 7.53400 | 7.07000 | 15.7480 | 15.2225 | 17.3880 | 19.6775 | 19.7900 | 19.7800 | 20.3775 | 22.2100 | 22.2475 | 24.1967 | 20.8800 | 22.5067 | 20.4400 | 13.9240 | 10.9875 |
| Riociguat 0.5 mg | 8.11903 | 8.07571 | 16.1241 | 15.5680 | 18.0884 | 20.6211 | 20.9084 | 19.5537 | 22.0844 | 21.5792 | 25.2647 | 26.4806 | 25.9674 | 25.3863 | 25.4212 | 10.9825 | 8.7147 |
Arterial blood samples will be obtained before, during, and after the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Samples will be obtained during the fifth minute of rest prior to exercise, during the third minute of each exercise level (referred to as stage below) and during the fifth minute post exercise. Cardiac output (CO) will be calculated using the Fick Principle: CO = V̇O2/(CaO2 - Cv̄O2) where CaO2 and Cv̄O2 represent the arterial and mixed venous oxygen content, respectively. CaO2 and CvO2 will be determined from analysis of the arterial blood samples using an IL GEM 4000 analyzer. VO2 will be reported as the final 30 secon average value of each stage. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | L/min (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 6.60219 | 8.98119 | 14.6762 | 14.7501 | 16.8736 | 16.8648 | 18.4603 | 18.0927 | 20.6738 | 20.8798 | 22.5701 | 21.9477 | 22.8612 | 23.0227 | 22.0850 | 22.5198 | 11.9949 | 10.9727 |
Subject arterial oxygen saturation (SaO2) will be periodically monitored at fixed intervals via arterial blood gas measurements during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | % oxygen saturation (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 85.4400 | 83.9000 | 74.2600 | 70.9800 | 70.9200 | 69.9800 | 67.1750 | 67.7500 | 68.9500 | 68.3500 | 68.825 | 68.825 | 66.5000 | 64.8667 | 67.7000 | 82.0400 | 83.5400 |
| Riociguat 0.5 mg | 78.3333 | 81.9667 | 71.2800 | 72.5800 | 71.0800 | 73.4500 | 71.5250 | 72.2500 | 71.3400 | 70.9000 | 71.3250 | 70.1000 | 71.5000 | 67.3000 | 73.9667 | 76.3500 | 80.5833 |
Subject arterial oxygen saturation (SaO2) will be periodically monitored at fixed intervals via arterial blood gas measurements during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | % oxygen saturation (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 84.9364 | 84.4000 | 73.1545 | 74.0000 | 72.4800 | 74.2556 | 71.9333 | 73.5000 | 72.1250 | 72.0167 | 69.6333 | 72.5200 | 71.4750 | 71.9750 | 70.8500 | 68.7000 | 79.2182 | 81.2700 |
Subject pulmonary artery pressures will be continuously monitored during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | mm Hg (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 16.3800 | 17.4000 | 25.3600 | 25.0800 | 26.6600 | 27.4400 | 25.7000 | 26.8500 | 26.9750 | 27.4000 | 27.5000 | 28.1500 | 28.7667 | 29.4333 | 26.6000 | 19.3000 | 19.2800 |
| Riociguat 0.5 mg | 16.8667 | 16.6833 | 25.0000 | 26.1167 | 27.2800 | 27.0600 | 28.0200 | 28.0500 | 29.7400 | 29.3750 | 30.8400 | 28.5000 | 32.6500 | 36.1000 | 32.9333 | 18.9500 | 19.2167 |
Subject pulmonary artery pressures will be continuously monitored during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | mm Hg (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 15.6545 | 15.4900 | 26.9455 | 25.1545 | 26.5800 | 25.5100 | 26.4111 | 24.1375 | 27.2750 | 25.2167 | 28.0333 | 24.2000 | 25.9250 | 22.7000 | 20.4000 | 22.5000 | 19.1273 | 16.6700 |
Subject systemic arterial pressures will be continuously monitored via radial artery catheterization during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | mm Hg (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 96.5600 | 96.7600 | 100.1600 | 102.500 | 107.020 | 105.580 | 109.425 | 111.825 | 112.675 | 112.475 | 114.775 | 114.175 | 108.100 | 107.367 | 101.9 | 90.4800 | 95.3600 |
| Riociguat 0.5 mg | 87.8333 | 91.6000 | 93.5167 | 97.1167 | 105.480 | 107.260 | 107.580 | 114.65 | 113.140 | 117.025 | 116.500 | 124.800 | 115.900 | 143.1 | 122.700 | 89.500 | 92.0833 |
Subject systemic arterial pressures will be continuously monitored via radial artery catheterization during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | mm Hg (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 93.3182 | 91.8000 | 101.545 | 97.627 | 107.270 | 104.867 | 110.122 | 106.425 | 114.650 | 109.517 | 115.267 | 108.240 | 112.025 | 108.825 | 107.900 | 102.400 | 90.3545 | 81.7800 |
Subject ventilation rates will be monitored continuously using a multi-channel A/D converter (PowerLab™) connected to a personal computer, using Chart™ software (ADInstruments, Colorado Springs, CO) during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | L/min (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 18.2266 | 16.4128 | 46.0238 | 42.0435 | 63.2124 | 60.8040 | 70.9060 | 69.1603 | 89.3008 | 92.8173 | 113.354 | 118.521 | 137.837 | 134.869 | 126.447 | 41.7934 | 40.7953 |
| Riociguat 0.5 mg | 14.7634 | 17.5454 | 38.3134 | 40.3488 | 52.1473 | 59.9588 | 67.3315 | 73.6560 | 89.7233 | 97.2645 | 108.857 | 121.556 | 143.373 | 145.65 | 156.669 | 32.3927 | 29.6728 |
Subject ventilation rates will be monitored continuously using a multi-channel A/D converter (PowerLab™) connected to a personal computer, using Chart™ software (ADInstruments, Colorado Springs, CO) during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | L/min (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 16.8981 | 18.9289 | 40.8095 | 41.3605 | 64.6476 | 61.4905 | 81.5548 | 78.0649 | 102.499 | 96.850 | 132.789 | 126.372 | 153.233 | 151.843 | 173.819 | 156.978 | 38.1639 | 34.7268 |
Subject work rates at exhaustion (in watts) will be continuously monitored using an ergometer (exercise bicycle) during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | watts (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 0 | 0 | 50 | 50 | 75 | 75 | 100 | 100 | 125 | 125 | 150 | 150 | 175 | 175 | 200 | 0 | 0 |
| Riociguat 0.5 mg | 0 | 0 | 50 | 50 | 75 | 75 | 100 | 100 | 125 | 125 | 150 | 150 | 175 | 175 | 200 | 0 | 0 |
Subject work rates at exhaustion (in watts) will be continuously monitored using an ergometer (exercise bicycle) during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | watts (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 0 | 0 | 50 | 50 | 75 | 75 | 100 | 100 | 125 | 125 | 150 | 150 | 175 | 175 | 200 | 200 | 0 | 0 |
13 reviews available for nifedipine and Altitude Sickness
| Article | Year |
|---|---|
COVID-19 Lung Injury and High-Altitude Pulmonary Edema. A False Equation with Dangerous Implications.
Topics: Acetazolamide; Altitude Sickness; Betacoronavirus; Carbonic Anhydrase Inhibitors; Coronavirus Infect | 2020 |
Travelling safely to places at high altitude - Understanding and preventing altitude illness.
Topics: Acclimatization; Acetazolamide; Altitude; Altitude Sickness; Anticonvulsants; Antiemetics; Calcium C | 2017 |
Research advances in pathogenesis and prophylactic measures of acute high altitude illness.
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Calcium Channel Blockers; Carbonic Anhydrase Inhibi | 2018 |
[Visiting high altitudes--healthy persons and patients with risk diseases].
Topics: Acclimatization; Acetazolamide; Acute Disease; Altitude; Altitude Sickness; Anti-Inflammatory Agents | 2004 |
High altitude-induced pulmonary oedema.
Topics: Acclimatization; Altitude Sickness; Disease Susceptibility; Humans; Hypertension, Pulmonary; Nifedip | 2006 |
[Prevention and therapy of altitude sickness].
Topics: Acetazolamide; Altitude Sickness; Dexamethasone; Humans; Hyperbaric Oxygenation; Nifedipine | 1993 |
High-altitude pulmonary edema: current concepts.
Topics: Acclimatization; Altitude Sickness; Animals; Calcium Channel Blockers; Capillary Permeability; Disea | 1996 |
The role of drugs in high altitude disorders.
Topics: Acetazolamide; Altitude Sickness; Calcium Channel Blockers; Dexamethasone; Glucocorticoids; Humans; | 1996 |
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Calcium Channel Blockers; Confidence Intervals; Dex | 2000 |
[Mountaineering and altitude sickness].
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Brain Edema; Diuretics; Glucocorticoids; Humans; Mo | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
[Pathophysiology, prevention and therapy of altitude pulmonary edema].
Topics: Aldosterone; Altitude Sickness; Cell Membrane Permeability; Epinephrine; Humans; Hypertension, Pulmo | 1992 |
[Who gets altitude sickness?].
Topics: Altitude Sickness; Blood Pressure; Disease Susceptibility; Humans; Hypoxia; Mountaineering; Nifedipi | 1992 |
6 trials available for nifedipine and Altitude Sickness
| Article | Year |
|---|---|
Managing High-Altitude Pulmonary Edema with Oxygen Alone: Results of a Randomized Controlled Trial.
Topics: Adult; Altitude; Altitude Sickness; Anti-Inflammatory Agents; Combined Modality Therapy; Dexamethaso | 2016 |
Endothelin-1 in pulmonary hypertension associated with high-altitude exposure.
Topics: Adult; Altitude; Altitude Sickness; Arteries; Blood Gas Analysis; Double-Blind Method; Endothelins; | 1995 |
Nifedipine does not prevent acute mountain sickness.
Topics: Acute Disease; Adult; Altitude; Altitude Sickness; Disease Susceptibility; Double-Blind Method; Fema | 1994 |
[Low-concentration nitrous oxide inhalation in the treatment of high-altitude pulmonary edema].
Topics: Administration, Inhalation; Adult; Altitude Sickness; Aminophylline; Dexamethasone; Drug Therapy, Co | 1998 |
Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker.
Topics: Acute Disease; Administration, Sublingual; Adult; Altitude Sickness; Double-Blind Method; Humans; Hy | 1992 |
Prevention of high-altitude pulmonary edema by nifedipine.
Topics: Adult; Altitude Sickness; Blood Pressure; Delayed-Action Preparations; Female; Humans; Male; Middle | 1991 |
32 other studies available for nifedipine and Altitude Sickness
| Article | Year |
|---|---|
Delayed-Onset High Altitude Pulmonary Edema: A Case Report.
Topics: Adult; Altitude Sickness; Humans; Male; Nifedipine; Oxygen; Pulmonary Edema | 2019 |
[Acute mountain sickness : How can it be treated and how can it be avoided?].
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Anti-Inflammatory Agents; Dexamethasone; Diuretics; | 2014 |
Investigation of the Hepato-Protective Effects of Imdur in a Rat Model of Chronic Mountain Sickness.
Topics: Altitude Sickness; Animals; Biomarkers; Blood Pressure; C-Reactive Protein; Chronic Disease; Glutath | 2015 |
Role of acetazolamide and telmisartan/nifedipine-GITS combination in antagonizing the blood pressure rise induced by high altitude exposure.
Topics: Acetazolamide; Altitude; Altitude Sickness; Benzimidazoles; Benzoates; Blood Pressure; Gastrointesti | 2016 |
An insilico approach to high altitude pulmonary edema - Molecular modeling of human beta2 adrenergic receptor and its interaction with Salmeterol & Nifedipine.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Altitude Sickness; Amino Acid Sequence; Binding Site | 2008 |
[Serious and sometimes fatal consequences of high-altitude pulmonary oedema].
Topics: Acetazolamide; Acute Disease; Adult; Altitude Sickness; Fatal Outcome; Female; Glucocorticoids; Huma | 2008 |
High-altitude medicines: a short-term genotoxicity study.
Topics: Acetazolamide; Adult; Altitude Sickness; Analysis of Variance; Cell Survival; Cells, Cultured; Comet | 2010 |
Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness.
Topics: Acetazolamide; Acute Disease; Albuterol; Altitude Sickness; Brain Edema; Carbolines; Dexamethasone; | 2010 |
High-altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailability.
Topics: Adult; Altitude Sickness; Antihypertensive Agents; Female; Free Radicals; Hemodynamics; Humans; Hype | 2010 |
[Hemodynamic effects of aminophylline and nifedipine in patients with high altitude pulmonary edema].
Topics: Adult; Altitude; Altitude Sickness; Aminophylline; Humans; Hypertension, Pulmonary; Male; Nifedipine | 2004 |
Nifedipine for the treatment of high altitude pulmonary edema.
Topics: Adaptation, Physiological; Adult; Altitude Sickness; Bed Rest; Calcium Channel Blockers; Cross-Secti | 2012 |
Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB.
Topics: Altitude Sickness; Animals; Calcium Channel Blockers; Capillary Permeability; Disease Models, Animal | 2012 |
Medical and sporting ethics of high altitude mountaineering: the use of drugs and supplemental oxygen.
Topics: Acetazolamide; Altitude Sickness; Dexamethasone; Humans; Mountaineering; Nifedipine; Oxygen; Oxygen | 2012 |
Performance-enhancing drugs-commentaries.
Topics: Acetazolamide; Altitude Sickness; Dexamethasone; Humans; Mountaineering; Nifedipine; Oxygen; Oxygen | 2012 |
Management of high altitude pulmonary edema in the Himalaya: a review of 56 cases presenting at Pheriche medical aid post (4240 m).
Topics: Acetazolamide; Altitude Sickness; Dexamethasone; Emergency Treatment; Female; Humans; Hypertension, | 2013 |
[Acute mountain sickness and high-altitude pulmonary edema. How to protect the mountain climber from the effects of the "altitude haze"].
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Anti-Inflammatory Agents; Carbonic Anhydrase Inhibi | 2003 |
[Your patient wants to go to the mountains. You protect him from mountain sickness and altitude edema].
Topics: Acetazolamide; Altitude Sickness; Anticonvulsants; Brain Edema; Carbolines; Carbonic Anhydrase Inhib | 2005 |
Statement on high-altitude illnesses. An Advisory Committee Statement (ACS).
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Canada; Dexamethasone; Humans; Methazolamide; Nifed | 2007 |
Treatment of high altitude pulmonary edema at 4240 m in Nepal.
Topics: Acetazolamide; Adult; Albuterol; Altitude; Altitude Sickness; Bed Rest; Emergency Treatment; Female; | 2007 |
[Malaria prevention with mefloquine].
Topics: Altitude Sickness; Calcium Channel Blockers; Chloroquine; Drug Interactions; Humans; Malaria; Mefloq | 1995 |
[Acute mountain sickness and high altitude pulmonary edema].
Topics: Acetazolamide; Altitude Sickness; Dexamethasone; Humans; Nifedipine; Pulmonary Edema | 1993 |
[Altitude illness].
Topics: Acetazolamide; Adult; Altitude Sickness; Diuretics; Female; Humans; Male; Nifedipine; Pulmonary Edem | 1995 |
Death from high-altitude pulmonary edema preventable by appropriate treatment.
Topics: Altitude Sickness; Delayed-Action Preparations; Emergency Treatment; Humans; Nifedipine; Pulmonary E | 2000 |
Treatment of high-altitude pulmonary oedema.
Topics: Adult; Altitude Sickness; Female; Humans; Nifedipine; Pulmonary Edema | 1992 |
The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: a comparison.
Topics: Altitude Sickness; Echocardiography, Doppler; Hemodynamics; Humans; Hydralazine; Nifedipine; Phentol | 1992 |
High altitude sickness.
Topics: Acetazolamide; Altitude Sickness; Dexamethasone; Humans; Nifedipine; Oxygen Inhalation Therapy; Pulm | 1992 |
[Fibrin formation: not a cause but consequence of altitude pulmonary edema].
Topics: Acute Disease; Altitude Sickness; Fibrinopeptide A; Humans; Mountaineering; Nifedipine; Pulmonary Ed | 1992 |
Nifedipine for high altitude pulmonary oedema.
Topics: Altitude Sickness; Humans; Nifedipine; Pulmonary Edema | 1991 |
Blood rheology in acute mountain sickness and high-altitude pulmonary edema.
Topics: Acute Disease; Adult; Altitude Sickness; Blood Flow Velocity; Blood Viscosity; Erythrocyte Aggregati | 1991 |
When lungs on mountains leak. Studying pulmonary edema at high altitudes.
Topics: Altitude Sickness; Humans; Mountaineering; Nifedipine; Pulmonary Edema | 1991 |
Nifedipine for high altitude pulmonary oedema.
Topics: Acute Disease; Administration, Sublingual; Adult; Altitude Sickness; Delayed-Action Preparations; Ec | 1989 |
A case of high-altitude pulmonary edema treated with nifedipine.
Topics: Altitude Sickness; Emergencies; Humans; Hypoxia; Male; Nifedipine; Pulmonary Edema | 1987 |